Recombinant Bovine Growth Hormone vs Tertiary Butylhydroquinone: which is worse?

What is Recombinant Bovine Growth Hormone?

Recombinant bovine growth hormone (rBGH), also called recombinant bovine somatotropin (rBST), is a synthetically produced version of the naturally occurring cattle growth hormone, manufactured using genetically engineered E. coli bacteria. Injected into dairy cows, it increases milk production by 10-15%. It was FDA-approved in 1993 under the brand name Posilac (originally Monsanto, later Elanco).

What is Tertiary Butylhydroquinone?

Tertiary butylhydroquinone (TBHQ) is a synthetic phenolic antioxidant preservative derived from butane. It is one of the most potent antioxidants for polyunsaturated fats and oils and is commonly used in fast-food frying oils. Its chemical formula is C10H14O2.

Documented risks

Recombinant Bovine Growth Hormone: The central human health concern is that rBGH treatment significantly elevates insulin-like growth factor 1 (IGF-1) levels in treated cows' milk. IGF-1 is a naturally occurring growth hormone that promotes cell growth and division. Multiple epidemiological studies have associated elevated blood IGF-1 levels with increased cancer risk in humans. A 1998 study in The Lancet (Hankinson et al.) found that women with the highest IGF-1 blood levels had approximately 7 times the breast cancer risk compared to those with the lowest levels. A 2004 meta-analysis in JNCI (the Journal of the National Cancer Institute) confirmed significant associations between high IGF-1 levels and breast, prostate, and colorectal cancer risk. The mechanistic question is whether consuming rBGH-treated milk raises blood IGF-1 levels in humans. The FDA and WHO/FAO Codex Alimentarius concluded that IGF-1 in milk is a protein largely digested in the GI tract before absorption. Canadian regulatory researchers challenged this, arguing that pasteurization reduces proteases that would otherwise break down IGF-1, potentially allowing more intact IGF-1 to survive digestion. The Codex Alimentarius Commission made history in 1999 by declining to endorse rBST safety maximum residue limits — a split vote (33 in favor of the MRL, 29 against, with abstentions) demonstrating fundamental international disagreement. This is one of very few cases where Codex failed to establish a safety standard. Animal welfare is a second major concern: Health Canada's comprehensive 1999 review found that rBGH-treated cows had 25% higher rates of clinical mastitis, 50% higher lameness risk, increased reproductive problems, and shortened productive lifespans, requiring substantially more antibiotic treatment — an antibiotic resistance concern. Canada rejected rBGH approval in 1999 after its scientific review; the EU banned it in 1999.

Tertiary Butylhydroquinone: At high doses in animal studies, TBHQ has been shown to cause precancerous stomach lesions (squamous cell hyperplasia) in female rats. A study in Food and Chemical Toxicology documented these dose-dependent precancerous changes. The FDA limits TBHQ to 0.02% of fat content, reflecting dose-dependent safety thresholds. Immune function concerns emerged from research published around 2019-2020. A study (Farouk Musa and colleagues) found that TBHQ impaired the adaptive immune response to influenza in mouse models, including reduced effectiveness of influenza vaccination. EWG highlighted this research in its analysis. These findings have not been confirmed in human clinical trials but raised new dimensions of concern beyond cancer. Neurotoxicity: animal studies have documented TBHQ can cause precursors to certain types of cell injury in neural tissue at high doses, though effects at typical dietary exposure are not established. Allergic reactions including urticaria and contact dermatitis from TBHQ-containing cosmetics and personal care products are documented in dermatology literature. Japan banned TBHQ for food use. The EU restricts it in baby food (completely banned) and in adult food categories with maximum permitted levels. Australia and the UK restrict it.